Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 2, 2012, Pages 145-155

  Arora, Anil ^a   Sharma, Praveen ^a  

^a SIR GANGA RAM HOSPITAL   (India)

Author keywords

Fibrosis; NAFLD; NASH

Indexed keywords

ADIPONECTIN; ANGIOPOIETIN; ANGIOPOIETIN LIKE PROTEIN 3; C REACTIVE PROTEIN; CHEMERIN; COLLAGEN TYPE 4; CYTOKERATIN 18; ENDOTHELIN 1; FAS ANTIGEN; INTERLEUKIN 6; LEPTIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PENTRAXIN 3; PRASTERONE; PROLINE DIPEPTIDASE; RETINOL BINDING PROTEIN 4; THIOREDOXIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACTITEST; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANALYTIC METHOD; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BAAT SCORE; BARD SCORE; BLOOD CELL COUNT; CLINICAL ASSESSMENT TOOL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MARKER; ECHOGRAPHY; ELASTOGRAPHY; ELF TEST; FIB 4 TEST; FIBROMAX; FIBROMETER; FIBROTEST; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; INFLAMMATION; LABORATORY TEST; LIVER CELL; LIVER FIBROSIS; MAGNETIC RESONANCE ELASTOGRAPHY; NASHTEST; NON INVASIVE PROCEDURE; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE STRESS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTHROMBIN TIME; PROTON NUCLEAR MAGNETIC RESONANCE; SCORING SYSTEM; STEATOTEST; TRANSIENT ELASTOGRAPHY;

EID: 84864109071     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60103-0     Document Type: Article

References (102)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005, 42:44-52.
3. Machado M, Marques-Vidal P, Cortez-Pinto H Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006, 45:600-606.
4. Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995, 40:2002-2009.
5. Franzese A, Vajro P, Argenziano A, et al. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997, 42:1428-1432.
6. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
7. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
8. Angulo P Long-term mortality in nonalcoholic fatty liver disease: is liver histology of any prognostic significance?. Hepatology 2010, 51:373-375.
9. Day CP Natural history of NAFLD: remarkably benign in the absence of cirrhosis. Gastroenterology 2005, 129:375-378.
10. Teli MR, James OF, Burt AD, Bennett MK, Day CP The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
11. Dam-Larsen S, Becker U, Franzmann MB, Larsen K, Christoffersen P, Bendtsen F Final results of a long-term, clinical follow-up in fatty liver patients. Scand J Gastroenterol 2009, 44:1236-1243.
12. Wong VW, Wong GL, Choi PC, et al. Disease progression of nonalcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut 2010, 59:969-974.
13. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
14. Adams LA, Sanderson S, Lindor KD, Angulo P The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005, 42:132-138.
15. Starley BQ, Calcagno CJ, Harrison SA Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010, 51:1820-1832.
16. Costera L, Negre I, Samii K, Buffet C Pain experienced during percutaneous liver biopsy. Hepatology 1999, 30:1529-1530.
17. Piccinino F, Sagnelli E, Pasquale G, Giusti G Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986, 2:165-173.
18. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005, 128:1898-1906.
19. Merriman RB, Ferrell LD, Patti MG, et al. Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006, 44:874-880.
20. Cadranel JF, Rufat P, Degos F Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
21. Bedossa P, Dargère D, Paradis V Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
22. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003, 37:1286-1292.
23. Fracanzani AL, Valenti L, Bugianesi E, et al. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008, 48:792-798.
24. Angulo P, Keach JC, Batts KP, Lindor KD Independent predictors of liver fibrosis in patients with non-alcoholic steatohepatitis. Hepatology 1999, 30:1356-1362.
25. Ruffillo G, Fassio E, Alvarez E, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. J Hepatol 2011, 54:160-163.
26. McPherson S, Stewart SF, Henderson E, Burt AD, Day CP Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut 2010, 59:1265-1269.
27. Tahan V, Canbakan B, Balci H, et al. Serum (gamma-glutamyl-transpeptidase) distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology 2008, 55:1433-1438.
28. Shaheen AA, Myers RP Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology 2007, 46:912-921.
29. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009, 50:165-173.
30. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
31. Loaeza-del-Castillo A, Paz-Pineda F, Oviedo-Cardenas E, Sanchez-Avila F, Vargas-Vorackova F AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis. Ann Hepatol 2008, 7:350-357.
32. Fujii H, Enomoto M, Fukushima W, et al. Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol 2009, 44:608-614.
33. Manousou P, Kalambokis G, Grillo F, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver Int 2011, 31:730-739.
34. Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012, 55:77-85.
35. Sanyal AJ American Gastroenterological Associatio. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology 2002, 123:1705-1725.
36. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001, 21:17-26.
37. Mishra P, Younossi ZM Abdominal ultrasound for diagnosis of nonalcoholic fatty liver disease (NAFLD). Am J Gastroenterol 2007, 102:2716-2717.
38. Strauss S, Gavish E, Gottlieb P, Katsnelson L Interobserver and intraobserver variability in the sonographic assessment of fatty liver. AJR Am J Roentgenol 2007, 189:W320-W323.
39. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur J Gastroenterol Hepatol 2009, 21:504-511.
40. Iijima H, Moriyasu F, Tsuchiya K, et al. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res 2007, 37:722-730.
41. Davidson LE, Kuk JL, Church TS, Ross R Protocol for measurement of liver fat by computed tomography. J Appl Physiol 2006, 100:864-868.
42. Park SH, Kim PN, Kim KW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology 2006, 239:105-112.
43. Szczepaniak LS, Nurenberg P, Leonard D, et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Am J Physiol Endocrinol Metab 2005, 288:E462-E468.
44. van Werven JR, Hoogduin JM, Nederveen AJ, et al. Reproducibility of 3 Tesla magnetic resonance spectroscopy for measuring hepatic fat content. J Magn Reson Imaging 2009, 30:444-448.
45. Guiu B, Petit JM, Loffroy R, et al. Quantification of liver fat content: comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy. Radiology 2009, 250:95-102.
46. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol 2007, 5:1207-1208.
47. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008, 135:32-40.
48. Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011, 106:1255-1263.
49. Osakabe K, Ichino N, Nishikawa T, et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol 2011, 46:1324-1334.
50. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012, 61:409-415. [Epub 2011 Aug 16].
51. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010, 51:454-462.
52. de Lédinghen V, Vergniol J, Foucher J, El-Hajbi F, Merrouche W, Rigalleau V Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int 2010, 30:1043-1048.
53. Yoneda M, Yoneda M, Fujita K, et al. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007, 56:1330-1331.
54. Musso G, Gambino R, Cassader M, Pagano G Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011, 43:617-649.
55. Castéra L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350.
56. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut 2008, 57:1441-1447.
57. Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterol 2010, 10:67.
58. Fujii H, Enomoto M, Fukushima W, Tamori A, Sakaguchi H, Kawada N Applicability of BARD score to Japanese patients with NAFLD. Gut 2009, 58:1566-1567. [Author reply 1567].
59. Yang HR, Kim HR, Kim MJ, Ko JS, Seo JK Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease. World J Gastroenterol 2012, 18:1525-1530.
60. Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009, 7:1104-1112.
61. Sumida Y, Yoneda M, Hyogo H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol 2012, 12:2.
62. Cales P, Oberti F, Michalak S, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381.
63. Calès P, de Ledinghen V, Halfon P, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008, 28:1352-1362.
64. Armstrong MJ, Houlihan DD, Bentham L, et al. Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. J Hepatol 2012, 56:234-240.
65. Ratziu V, Giral P, Charlotte F, et al. Liver fibrosis in overweight patients. Gastroenterology 2000, 118:1117-1123.
66. Shaheen AA, Wan AF, Myers RP FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102:2589-2600.
67. Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007, 7:40.
68. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointest Liver Dis 2008, 17:187-191.
69. Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T FibroMAX: towards a new universal biomarker of liver disease?. Expert Rev Mol Diagn 2007, 7:481-490.
70. Dixon JB, Bhathal PS, O'Brien PE Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001, 121:91-100.
71. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA Clinical model for distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic fatty liver disease. Liver Int 2006, 26:151-156.
72. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP Nonalcoholic fatty liver disease in severely obese subjects. Am J Gastroenterol 2007, 102:399-408.
73. Poynard T, Ratziu V, Charlotte F, et al. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 2006, 6:34.
74. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005, 25:779-786.
75. Rosenberg WM, Voelker M, Thiel R, et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
76. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in non-alcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 2008, 47:455-460.
77. Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010, 59:1245-1251.
78. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 2004, 40:46-54.
79. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in nonalcoholic fatty liver disease. Liver Int 2009, 29:1431-1438.
80. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study. Hepatology 2009, 50:1072-1078.
81. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related non-alcoholic steatohepatitis (NASH). Obes Surg 2008, 18:1430-1437.
82. Younossi ZM, Page S, Rafiq N, et al. A biomarker panel for nonalcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obes Surg 2011, 21:431-439.
83. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2005, 11:255-259.
84. Kaneda H, Hashimoto E, Yatsuji S, Tokushige K, Shiratori K Hyaluronic acid levels can predict severe fibrosis and platelet counts can predict cirrhosis in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2006, 21:1459-1465.
85. Lesmana CR, Hasan I, Budihusodo U, et al. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. J Dig Dis 2009, 10:201-206.
86. Yoneda M, Yoneda M, Mawatari H, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with non-alcoholic fatty liver disease (NAFLD). Dig Liver Dis 2008, 40:371-378.
87. Santos VN, Leite-Mor MM, Kondo M, et al. Serum laminin, type IV collagen and hyaluronan as fibrosis markers in non-alcoholic fatty liver disease. Braz J Med Biol Res 2005, 38:747-753.
88. Haukeland JW, Damås JK, Konopski Z, et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J Hepatol 2006, 44:1167-1174. [Epub 2006 Mar 20].
89. Hui JM, Farrell GC, Kench JG, George J High sensitivity C-reactive protein values do not reliably predict the severity of histological changes in NAFLD. Hepatology 2004, 39:1458-1459.
90. Tarantino G, Conca P, Pasanisi F, et al. Could inflammatory markers help diagnose nonalcoholic steatohepatitis?. Eur J Gastroenterol Hepatol 2009, 21:504-511.
91. Sumida Y, Nakashima T, Yoh T, et al. Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease. J Hepatol 2003, 38:32-38.
92. Kayadibi H, Gültepe M, Yasar B, et al. Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 2009, 54:1764-1771.
93. Charlton M, Angulo P, Chalasani N, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 2008, 47:484-492.
94. Tamimi TI, Elgouhari HM, Alkhouri N, et al. An apoptosis panel for nonalcoholic steatohepatitis diagnosis. J Hepatol 2011, 54:1224-1229.
95. Yilmaz Y, Ulukaya E, Gul OO, et al. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease. Clin Biochem 2009, 42:802-807.
96. Alkhouri N, Lopez R, Berk M, Feldstein AE Serum retinolbinding protein 4 levels in patients with nonalcoholic fatty liver disease. J Clin Gastroenterol 2009, 43:985-989.
97. Degertekin B, Ozenirler S, Elbeg S, Akyol G The serum endothelin-1 level in steatosis and NASH, and its relation with severity of liver fibrosis. Dig Dis Sci 2007, 52:2622-2628.
98. Yilmaz Y, Ulukaya E, Atug O, Dolar E Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. Eur J Gastroenterol Hepatol 2009, 21:1247-1251.
99. Kukla M, Zwirska-Korczala K, Hartleb M, et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand J Gastroenterol 2010, 45:235-242.
100. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology 2005, 42:665-674.
101. Wieckowska A, McCullough AJ, Feldstein AE Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 2007, 46:582-589.
102. Trak-Smayra V, Dargere D, Noun R, et al. Serum proteomic profiling of obese patients: correlation with liver pathology and evolution after bariatric surgery. Gut 2009, 58:825-832. [Epub 2008 Apr 10].